Palbociclib plus letrozole versus weekly paclitaxel, both in combination with trastuzumab plus pertuzumab, as neoadjuvant treatment for patients with HR+/HER2+ early breast cancer: primary results from the randomized phase II TOUCH trial (IBCSG 55-17).

Auteurs

Malorni L, Tyekucheva S, Gombos A, Hasler-Strub U, Zamagni C, Chakiba-Brugère C, Colleoni M, Mueller A, Minisini AM, Taylor D, Salmon JP, Gallerani E, Cariello A, Fontana A, Roschitzki-Voser H, Kammler R, Ruepp B, Loi S, Viale G, Regan MM, Brain E, Biganzoli L

  • Date de publication

    October 2025

  • Type

    Article

  • Review

    Ann Oncol

  • Researcher's name

    GOMBOS ANDREA

  • Hôpital

    Institut Jules Bordet

  • Service

    Médecine Oncologique

  • PMID

    41109527

  • DOI

    10.1016/j.annonc.2025.10.016